Alexion Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ALXN Alexion Pharmaceuticals Inc
IWN iShares Russell 2000 Value ETF
XNXCX Nuveen California Select Tax-Free Income Portfolio
AMGN Amgen Inc
AMSC American Superconductor Corp
CVBF CVB Financial Corp
PHG Koninklijke Philips NV
IVR Invesco Mortgage Capital Inc
CORE Core-Mark Holding Company Inc
ATMH All Things Mobile Analytic Inc
Go

Health Care : Biotechnology | Mid Cap Blend
Company profile

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.

Closing Price
$156.70
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
2,949,959
0
  • Prev Close
    156.70
  • Today's Open
    --
  • Day's Range
    --
  • Avg Vol (10-day)
    2.9M
  • Last (time)
    4:00p ET 01/15/21
  • Last (size)
    20.6K
  • 52-Wk Range
    72.67 - 160.03
    LowHigh
  • (03/16/20 - 12/16/20)
    2.08%
  • 46.6%
  • Market Cap
    34.3B
  • Shares Outstanding
    218.7M
  • 4.27
  • 36.70x
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 1.2
  • 90.31
  • (% of float 12/31/20)
    1.68

Latest News

January 13, 2021
5:14 pm ET
MarketWatch
5:14 pm ET
MarketWatch
1:20 pm ET
BusinessWire
January 12, 2021
4:00 am ET
BusinessWire
January 11, 2021
12:01 am ET
PR Newswire
January 08, 2021
7:48 am ET
MarketWatch
January 07, 2021
1:55 pm ET
Globe Newswire
January 05, 2021
1:30 pm ET
BusinessWire
December 18, 2020
9:00 pm ET
PR Newswire
6:49 am ET
Globe Newswire
1:20 am ET
Accesswire
December 16, 2020
8:09 am ET
MarketWatch
December 15, 2020
7:44 pm ET
Globe Newswire
10:31 am ET
Globe Newswire
5:00 am ET
BusinessWire
December 14, 2020
6:20 pm ET
Globe Newswire
4:05 pm ET
PR Newswire
9:49 am ET
MarketWatch
9:07 am ET
MarketWatch
8:53 am ET
MarketWatch
8:35 am ET
MarketWatch
8:30 am ET
PR Newswire
8:22 am ET
MarketWatch
December 13, 2020
8:58 pm ET
PR Newswire
December 12, 2020
6:07 am ET
BusinessWire
4:48 am ET
BusinessWire
November 23, 2020
1:20 am ET
Accesswire
November 19, 2020
11:00 pm ET
BusinessWire
November 10, 2020
4:00 am ET
BusinessWire
November 04, 2020
8:55 am ET
BusinessWire
8:50 am ET
BusinessWire
October 29, 2020
6:01 am ET
Accesswire
3:30 am ET
BusinessWire
October 26, 2020
7:50 am ET
Globe Newswire
October 22, 2020
8:30 am ET
PR Newswire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.